10/12/2026
No clear reduction in deaths: that was the main finding in the TESTS thymosin alpha-1 trial. Researchers enrolled 1,106 adults with sepsis and analyzed 1,089. Deaths within 28 days were 23.4% with thymosin alpha-1 and 24.1% with placebo. These 2025 results do not establish cold prevention, safety for self-use or benefits from Kaven products.
Which study detail should we unpack next: who was studied, or what was measured?
Source: Wu and colleagues, BMJ (2025), including the published correction.
https://www.bmj.com/content/388/bmj-2024-082583
https://www.bmj.com/content/389/bmj.r1098.full.pdf